Two decades of HIV infection in a cohort of haemophilic individuals: Clinical outcomes and response to highly active antiretroviral therapy

AIDS

Volumn 14, Issue 8, 2000, Pages 1001-1007

  Sabin, Caroline A ^a,b   Yee, Thynn Thynn ^a   Devereux, Helen ^a   Griffioen, Anja ^a   Loveday, Clive ^a   Phillips, Andrew N ^a   Lee, Christine A ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b Royal Free Campus ^*  (United Kingdom)

Author keywords

Antiretroviral therapy; Haemophilia; Hepatitis C virus; Highly active antiretroviral therapy

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; INDINAVIR; LAMIVUDINE; LOVIRIDE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; BREAST TUMOR; CHILD; CLINICAL TRIAL; COHORT ANALYSIS; DIABETES MELLITUS; HEMOPHILIA; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOMA; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SEROCONVERSION; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DISEASE PROGRESSION; HEMOPHILIA A; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD; VIREMIA;

EID: 0034040320     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200005260-00012     Document Type: Article

References (23)

1. 1. Lee CA, Webster A, Griffiths PD, Kernoff PBA. Symptomless HIV infection after more than ten years [letter]. Lancet 1990, 335:425-426.
2. 2. Darby SC, Ewart DW, Giangrande PLF, on behalf of the UK Haemophilia Centre Directors' Organization. Mortality before and after HIV infection in the complete UK population of haemophiliacs. Nature 1995, 377-79-82.
3. 3. Kernoff PBA, Lee CA, Karayiannis P, Thomas HC. High risk of non-A non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulin. Br J Haematol 1985, 60:469-479.
4. 4. Eyster ME, Diamondstone LS, Lien J, Ehmann WC, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. J Acquir Immune Defic Syndr 1993, 6:602-610.
5. 5. Telfer P, Sabin C, Devereux H, Scott F, Dusheiko G, Lee C. The progression of HCV-associated liver disease in a cohort of haemophilic patients. Br J Haematol 1994, 87:555-561.
6. 6. Yee T-T, Armolia P, Lee CA, Mire N, Giangrande PL. Protease inhibitors and unusual bleeding in haemophiliacs [letter]. Haemophilia 1997, 3:219-221.
7. 7. Lee CA, Phillips A, Elford J et al. The natural history of human immunodeficiency virus infection in a haemophilic cohort. Br J Haematol 1989, 73:228-234.
8. 8. Sabin CA, Devereux H, Phillips AN, Janossy G, Lee CA, Loveday C. The course of viral load throughout HIV infection. J Acquir Imm Defic Syndr 2000, 23:172-177.
9. 9. Ginsburg C, Salmon-Ceron D, Vassilief D, et al. Unusual occurrence of spontaneous haematomas in three asymptomatic HIV-infection haemophila patients a few days after the onset of ritonavir treatment [letter]. AIDS 1997, 11:388-389.
10. 10. Ahlbom A. Biostatistics for Epidemiologists. London: Lewis; 1993.
11. 11. SAS Institute: SAS/STAT User's Guide, Version 6. Cary: SAS Institute; 1992.
12. 12. Goedert JJ, Kessler CM, Aledort LM et al. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med 1989, 321:1141-1148.
13. 13. Astermark J, Johnsson H, Stigendal L, Lethagen S, Berntorp E. HIV disease progression in Swedish haemophiliacs and the influence of replacement therapy. Haemophilia 1997, 3:277-282
14. 14. Sabin CA, Elford J, Phillips AN, Janossy G, Lee CA. Prophylaxis for Pneumocystis carinii pneumonia: its impact on the natural history of HIV infection in men with haemophilia. Haemophilia 1995, 1:37-44.
15. 15. Rabkin CS, Goedert JJ, Biggar RJ, Yellin F, Blattner WA. Kaposi's sarcoma in three HIV-1-infected cohort, J Acquir Imm Defic Syndr 1990, 3(suppl 1):S38-S43.
16. 16. Simpson GR, Schultz TF, Whitby D et al. Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet 1996, 348:1133-1138.
17. 17. Darby SC, Ewart DW, Giangrande PLF et al. Mortality from liver cancer and liver disease in haemophilic men and boys in the UK given blood products contaminated with hepatitis C. Lancet 1997, 350:1425-1431.
18. 18. Eyster ME, Fried MW, Di Disceglie AM, Goedert JJ. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood 1994, 84: 1020-1023.
19. 19. Merry C, McMahon C, Ryan M, O'Shea E, Mulcahy F, Smith OP. Successful use of protease inhibitors in HIV-infected haemophilia patients. Br J Haematol 1998, 101:475-479.
20. 20. Lederman MM, Connick E, Landay A et al. Immunological responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS Clinical Trials Group protocol 315. J Infect Dis 1998, 178:70-79.
21. 21. Kaufmann GR, Duncombe C, Cunningham P et al. Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1-infected individuals. AIDS 1998, 12:1625-1630.
22. 22. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353: 2093-2099.
23. 23. Walli R, Herfort O, Michl GM et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998, 12:F167-F173.